Why BridgeBio Pharma is back on investor radars

BridgeBio Pharma (BBIO) has drawn fresh attention after releasing long-term data for its ATTR-CM drug acoramidis and filing an FDA New Drug Application for BBP-418 in limb-girdle muscular dystrophy.

These product updates, together with new analyst coverage highlighting BridgeBio's broader rare disease pipeline, have refocused the market on how its existing approvals and late-stage programs might shape the company’s future profile.

BridgeBio Pharma's share price has eased from recent highs, with a 1 month share price return of 7.46% but a 3 month share price return decline of 5.71%, while its 1 year total shareholder return of 114.03% and 3 year total shareholder return of almost 4x suggest strong longer term momentum around its rare disease story.

If this kind of pipeline driven move has your attention, it could be a good moment to scan the broader healthcare AI theme and see what stands out in the 31 healthcare AI stocks

With BBIO trading at US$74.59, sitting on very large 3 year total returns, positive revenue growth but a US$724.9m net loss, is the rare disease pipeline still underappreciated, or is the market already pricing in future growth?

Most Popular Narrative: 25.4% Undervalued

At a last close of $74.59 versus a narrative fair value of $100.05, the most followed view sees BridgeBio as materially mispriced, hinging on aggressive growth and margin assumptions.

The company's late-stage pipeline, with three Phase III readouts imminent across high unmet need rare disease indications, positions BridgeBio to leverage advancements in biotechnology for potential first-to-market and best-in-class therapies, creating the opportunity for multiple revenue inflection points and margin improvement as the portfolio diversifies. Established commercial and patient support infrastructure, enabled by strong sales execution and white-glove access models, is expected to be redeployed for future launches, reducing incremental fixed costs per new product and supporting long-term operational leverage and net margin expansion.

Curious what earnings path and margin shift support that $100.05 figure? The narrative leans on rapid revenue expansion, a sharp profitability swing, and a rich future earnings multiple to tie it all together.

Result: Fair Value of $100.05 (UNDERVALUED)

However, this depends on Attruby remaining dominant and key late stage trials avoiding setbacks, since any safety, competition or regulatory surprises could quickly reset expectations.

Another View: Rich Sales Multiple Keeps Expectations High

While the narrative and DCF style work suggest BBIO looks 25.4% undervalued versus a fair value of $100.05, the current P/S of 28.8x tells a tougher story. That is much higher than the US Biotechs industry at 11x and a fair ratio of 19.7x, as well as above peers at 13.4x, which points to real valuation risk if sentiment cools.

For a closer look at how those sales based metrics stack up and where the ratio could drift over time, have a read of the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, you do not need to wait to form your own view. Weigh the trade off by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If BBIO has sharpened your interest in focused, data driven research, you may wish to widen your watchlist and see what else could deserve attention.

• Target steadier compounding potential by scanning companies with robust payouts and business models through the 11 dividend fortresses.
• Hunt for mispriced quality by reviewing companies that screen well on fundamentals in the screener containing 23 high quality undiscovered gems.
• Prioritise resilience by checking businesses that pair balance sheet strength with solid operations in the solid balance sheet and fundamentals stocks screener (41 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.